Bernd Bokemeyer

6.9k total citations
144 papers, 2.4k citations indexed

About

Bernd Bokemeyer is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Bernd Bokemeyer has authored 144 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 107 papers in Genetics, 90 papers in Epidemiology and 40 papers in Surgery. Recurrent topics in Bernd Bokemeyer's work include Inflammatory Bowel Disease (106 papers), Microscopic Colitis (77 papers) and Eosinophilic Esophagitis (29 papers). Bernd Bokemeyer is often cited by papers focused on Inflammatory Bowel Disease (106 papers), Microscopic Colitis (77 papers) and Eosinophilic Esophagitis (29 papers). Bernd Bokemeyer collaborates with scholars based in Germany, United States and United Kingdom. Bernd Bokemeyer's co-authors include Andreas Stallmach, Jürgen M. Stein, Stefan Schreiber, Axel Dignaß, Christoph Gasché, Daniel C. Baumgart, И. Л. Халиф, Rayko Evstatiev, Tariq Iqbal and Philippe Marteau and has published in prestigious journals such as Gastroenterology, PLoS ONE and The Journal of Urology.

In The Last Decade

Bernd Bokemeyer

128 papers receiving 2.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Bernd Bokemeyer 1.4k 1.1k 644 499 296 144 2.4k
Nicolas Williet 1.3k 1.0× 1.1k 1.1× 585 0.9× 249 0.5× 146 0.5× 70 2.2k
Simone Saibeni 1.1k 0.8× 809 0.8× 850 1.3× 313 0.6× 71 0.2× 99 2.3k
Mark T. Osterman 2.1k 1.6× 1.7k 1.6× 781 1.2× 245 0.5× 158 0.5× 157 3.2k
B. A. Chapman 485 0.4× 740 0.7× 762 1.2× 216 0.4× 179 0.6× 44 2.0k
Waqqas Afif 2.0k 1.5× 1.7k 1.6× 775 1.2× 153 0.3× 131 0.4× 143 2.8k
Henrik Hjortswang 1.3k 1.0× 1.3k 1.2× 456 0.7× 503 1.0× 232 0.8× 75 2.2k
Stéphane Nahon 977 0.7× 885 0.8× 645 1.0× 116 0.2× 47 0.2× 91 1.7k
Francisco Portela 1.3k 0.9× 1.0k 1.0× 929 1.4× 96 0.2× 45 0.2× 129 2.1k
Frank I. Scott 607 0.4× 523 0.5× 547 0.8× 94 0.2× 53 0.2× 118 1.8k
Palle Bager 541 0.4× 414 0.4× 311 0.5× 330 0.7× 150 0.5× 46 1.2k

Countries citing papers authored by Bernd Bokemeyer

Since Specialization
Citations

This map shows the geographic impact of Bernd Bokemeyer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bernd Bokemeyer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bernd Bokemeyer more than expected).

Fields of papers citing papers by Bernd Bokemeyer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bernd Bokemeyer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bernd Bokemeyer. The network helps show where Bernd Bokemeyer may publish in the future.

Co-authorship network of co-authors of Bernd Bokemeyer

This figure shows the co-authorship network connecting the top 25 collaborators of Bernd Bokemeyer. A scholar is included among the top collaborators of Bernd Bokemeyer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bernd Bokemeyer. Bernd Bokemeyer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Friedrich, Benjamin, et al.. (2025). Six-Year Observation Data Reveal Reduction in Concomitant Steroid Overuse for Inflammatory Bowel Disease in Germany. Inflammatory Bowel Diseases. 31(11). 2996–3002.
2.
Bokemeyer, Bernd, Sandra Plachta‐Danielzik, Romina di Giuseppe, et al.. (2025). Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment. Journal of Crohn s and Colitis. 19(4). 1 indexed citations
3.
Bokemeyer, Bernd, et al.. (2025). Burden of coeliac disease in Germany: real-world insights from a large retrospective health insurance claims database analysis. Therapeutic Advances in Gastroenterology. 18. 1128497779–1128497779.
4.
Nissinen, R, et al.. (2024). Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis. Therapeutic Advances in Gastroenterology. 17. 1118445264–1118445264. 2 indexed citations
5.
Sulais, Eman Al, Édouard Louis, Bernd Bokemeyer, et al.. (2024). Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire. Journal of Crohn s and Colitis. 19(2). 2 indexed citations
6.
Bokemeyer, Bernd, Sandra Plachta‐Danielzik, Eugen I. Urzica, et al.. (2024). Inflammatory bowel disease (IBD) patients with impaired quality of life on biologic therapy benefit from the support of an IBD nurse specialist: Results of a randomised controlled trial in Germany (IBDBIO‐ASSIST study). Alimentary Pharmacology & Therapeutics. 59(9). 1082–1095. 2 indexed citations
7.
Schulz, F., Ann Christina Foldenauer, A Thomann, et al.. (2024). Women with IBD Show Higher Psychophysiological Burden in Comparison to Men with IBD. Journal of Clinical Medicine. 13(24). 7806–7806. 2 indexed citations
8.
9.
Bokemeyer, Bernd, Sandra Plachta‐Danielzik, Romina di Giuseppe, et al.. (2023). Evaluation of a downstaging, bidirectional version of the Montreal classification of Crohn's disease: Analysis of 5‐year follow‐up data from the prospective BioCrohn study. Alimentary Pharmacology & Therapeutics. 58(1). 35–47. 2 indexed citations
10.
Bokemeyer, Bernd, et al.. (2023). Rates of clinical remission and inadequate response to advanced therapies among patients with ulcerative colitis in Germany. International Journal of Colorectal Disease. 38(1). 116–116. 7 indexed citations
11.
Bokemeyer, Bernd, Sandra Plachta‐Danielzik, Wolfgang Mohl, et al.. (2023). OP36 Real-world evidence on comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with propensity score adjustment: two-year maintenance phase results from the prospective observational RUN-CD study. Journal of Crohn s and Colitis. 17(Supplement_1). i50–i50. 1 indexed citations
12.
Plachta‐Danielzik, Sandra, Bernd Bokemeyer, Elisabeth Schnoy, et al.. (2023). P784 Real-world use and 6-month effectiveness of vedolizumab subcutaneous in IBD patients: results of the VEDO-IBD study. Journal of Crohn s and Colitis. 17(Supplement_1). i918–i919. 2 indexed citations
13.
Antolin‐Fontes, Beatriz, R Nissinen, Manuela Le Bars, et al.. (2022). Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data. Therapeutic Advances in Gastroenterology. 15. 1098313530–1098313530. 2 indexed citations
14.
Neumann, Helmut, Fabián Emura, Bernd Bokemeyer, et al.. (2020). Practical advice for management of inflammatory bowel diseases patients during the COVID‐19 pandemic: World Endoscopy Organization Statement. Digestive Endoscopy. 32(5). 658–662. 8 indexed citations
15.
Feagan, Brian G., Stefan Schreiber, Douglas C. Wolf, et al.. (2018). Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflammatory Bowel Diseases. 25(6). 1028–1035. 21 indexed citations
16.
Wittig, Bianca M., Robert Sabat, Ellen Witte‐Händel, et al.. (2017). Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis. Mucosal Immunology. 11(3). 846–860. 12 indexed citations
17.
Schreiber, Stefan, Heinz Hartmann, Wolfgang Kruis, et al.. (2016). [Inflammatory Bowel Disease Competence Network].. PubMed. 59(4). 465–74. 2 indexed citations
18.
Teich, Niels, Wolfgang Mohl, Bernd Bokemeyer, et al.. (2015). Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseases—A Prospective Study on Incidence and Severity. Journal of Crohn s and Colitis. 10(1). 61–68. 72 indexed citations
19.
Kruis, Wolfgang, Alexander Katalinic, Tobias Klugmann, et al.. (2012). Predictive factors for an uncomplicated long-term course of Crohn's disease: A retrospective analysis. Journal of Crohn s and Colitis. 7(7). e263–e270. 23 indexed citations
20.
Albert, Jörg, Wolfgang J. Köstler, Birgit Kaltz, et al.. (2008). Course of Crohn’s Disease Prior to Establishment of the Diagnosis. Zeitschrift für Gastroenterologie. 46(2). 187–192. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicolas Williet Breakdown of academic impact, for papers by Simone Saibeni Breakdown of academic impact, for papers by Mark T. Osterman Breakdown of academic impact, for papers by B. A. Chapman Breakdown of academic impact, for papers by Waqqas Afif Breakdown of academic impact, for papers by Henrik Hjortswang Breakdown of academic impact, for papers by Stéphane Nahon Breakdown of academic impact, for papers by Francisco Portela Breakdown of academic impact, for papers by Frank I. Scott Breakdown of academic impact, for papers by Palle Bager
Rankless by CCL
2026